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NIH mission and global health
The mission of the US National Institutes of Health (NIH),
Department of Health and Human Services, includes support
for biomedical research to extend healthy life by reducing the
burdens of illness worldwide. To this end, the NIH’s Office of
Technology Transfer (OTT) seeks to address gaps related to
the availability of NIH inventions and to enhance the acces-
sibility of its research to people around the world. With its
leadership in biomedical research and innovation, as well as
the management of technology commercialization across
sectors, the OTT is in a key position to provide leadership in
this area and to help other countries formulate appropriate
technology-transfer procedures that are compatible with such
activities in the developed world [http://www.iipi.org/activi-
ties/projects_tech_transfer.htm].
To illustrate the global reach of NIH international activi-
ties, Table 1 lists some of the countries with which it has exe-
cuted grants and contracts. The OTT has already been suc-
cessfully moving Public Health Services technologies to
institutions in developing countries, such as China and
Brazil, based on public-health needs and research and devel-
opment (R&D) commercialization capabilities, but has found
only a few institutions in even fewer countries to be familiar
with the patenting or licensing process and/or able to enter
into negotiations. International property rights are considered
a critical currency in technology transfer and innovation
(Intellectual Property Rights: Implications for Development
International Centre for Trade and Sustainable Development
and United Nations Conference on Trade and Development,
2003). With its leadership in biomedical research, the NIH is
in a position to play a significant role in international tech-
nology transfer. In presenting the NIH Roadmap Initiative,
current NIH Director Dr. Zerhouni has stressed the need to
position NIH in addressing the evolving public-health chal-
lenges of the 21st century. The Roadmap would target the
enhancement of “public-private partnerships [which] have
become a model for advancing science and communicating
results of medical advances to improve the quality of life for
all people.” 
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Table 1. Some of the countries that receive NIH grants and contracts
Thailand
India
China
South Korea
Pakistan
Indonesia
Nepal
Egypt
Kenya
Ghana
South Africa
Tanzania
Mali
Nigeria
Morocco
Canada
Australia
Israel
Japan
UK
France
Italy
Spain
Russia
Hungary
Costa Rica
Jamaica
Trinidad & Tobago
Mexico
Brazil
Argentina
Guatemala
Chile
Colombia
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Technology transfer: a tool to move
biomedical research in developing
countries
With its significant role in technology transfer within the US for
over 15 years, the OTT has both the expertise and the long-
standing experience in moving technologies between the public
and private sectors to commercialization in the US and abroad
[http://www.iipi.org/activities/projects_tech_transfer.htm].
Indeed, 329 licenses have been executed to a foreign entity
out of 2715 executed licenses or license amendments and, in
fiscal year 2003, there were 19 foreign licenses executed out
of a total of 221 (of which, 145 were new licenses and 76
were amendments). As some developing countries (such as
China, India, Brazil, and South Africa) are now considered to
be emerging economies, with areas of sophisticated techno-
logical (biomedical R&D) capabilities, there is increasing
scope for intensifying technology transfers to such countries.
In its routine functions relating to intellectual property,
patents and licensing, and through its daily interactions with
NIH scientists, universities and industries, the NIH has been
at the forefront of this endeavor, making technologies acces-
sible to the public. Its activities have resulted in the outcome
of approximately 200 products, to-date through collabora-
tions with stakeholders, including private industry, academia,
governments, international organizations and private founda-
tions. These include HIVAB (AIDS test kit, Abbott), Videx
(ddI, BMS), Taxol (paclitaxel, BMS), Fludara (fludarabine,
Schering), Hivid (ddC, Roche), and Havrix (hepatitis A,
GSK).
The NIH has relatively strong portfolios in certain neg-
lected infectious disease areas (shown in Table 2), which have
not been fully used. Note that whilst there may be certain
technologies available for these diseases, they may either be
inaccessible to most developing-country markets due to cost
of complicated delivery mechanisms (as in the case of Lyme
disease), or may be obsolete (i.e. tuberculosis).
The OTT is increasingly active in exploring ways to
enhance the process of transferring such technologies to de-
veloping countries and has been scaling up its international
activities in recent months. Contacts are being developed
worldwide with R&D institutions in developing countries, in
both private and public sectors worldwide, in the drive to
market these technologies to parties interested in entering
developing-country markets. This has involved the proactive
search for potential developing-country partners in key neg-
lected disease areas, which include both communicable (i.e.
HIV/AIDS, dengue and rotavirus) and non-communicable
(i.e. cancer, diabetes) diseases.
Initial results and lessons learned
Through ongoing analysis of its own portfolio and the needs
and capabilities of developing countries, the OTT has found
that there is a niche for intellectual technology transfer that
does not jeopardize US techno-economic interests.
Congruently, it aims at providing solutions to the most socio-
economically harmful diseases. The OTT has already trans-
ferred early-stage technologies to public and private institu-
tions in India, China, and Mexico, whilst negotiations are in
progress with countries such as Brazil, South Korea,
Indonesia, and South Africa. Additionally, the OTT has
become an important part of inter-institutional product devel-
opments, for example with the conjugated meningococcal
vaccine (with the Program for Appropriate Technologies in
Health–PATH; World Health Organization [WHO] and man-
ufacturers in India for eventual distribution in Sub-Saharan
Africa, the Middle East, Latin America, the Caribbean, and
Eastern Europe). These licenses relate to diseases that lack a
profitable market, and are of little to no interest to firms in
developed countries, but—as we have already seen—can pro-
vide necessary medical solutions and the prospect of eco-
nomic growth to developing countries. 
The OTT has found that a holistic and flexible approach
to international technology transfer is required, removing the
possibility of developing the donor-recipient paradigm in
which there are unequal partnerships, and consequent prob-
lems with trust, commitment, and reliability. It involves direct
participation of local scientists and managers from indigent
countries with whom we conduct development agreements as
well as flexibility and determination on our part.
Future plans
Through its ongoing and intended activities in international
technology transfer, the OTT has the potential to make a con-
tribution to meeting the scientific, technological and health
needs of developing countries by enabling their scientific and
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Table 2. Examples of NIH intellectual property in neglected disease areas
Disease/therapeutic area Technologies Issued patents Patents pending
Dengue 22 1 113
Rotavirus 12 4 36
Human papilloma virus 15 14 56
Lyme disease 6 1 18
Tuberculosis 10 2 24
Malaria 29 176 78
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administrative staff to commercialize their home-grown tech-
nologies for the benefit of local and regional public health.
As the OTT’s interactions with developing countries mature
and expand, the next steps include an evaluation study that
will explore the needs and opportunities related to technolo-
gy transfer and the capacity building/training needs of insti-
tutions in developing countries. Areas that impact technolo-
gy-transfer outcomes will also be evaluated, such as policies
related to intellectual property, regulations, clinical trials,
intellectual property management capabilities, and legisla-
tion influencing public-private sector partnerships. 
Some organizations hold training courses and work-
shops, and provide guidance in technology transfer, which
may address important primary needs by providing some
exposure to this field. The OTT has ongoing dialogue with
different stakeholders in this area, including international
organizations, regional agencies, private foundations, and
professional societies. 
The OTT has been and will continue to look for ways to
provide input that is complementary to the missions of other
organization missions (including international organizations,
regional agencies, and private foundations) and to address the
different needs and challenges associated with global health
and technology transfer activities. In this way, we are system-
atically identifying and mapping ongoing work by such
organizations, which will clarify the nature and scope of gaps
in the capacity-building process and the international tech-
nology-transfer system. In turn, the OTT will use its experi-
ence to identify areas of greatest need and propose relevant
solutions to bridge those gaps. We will also continue and
enhance our contributions to hands-on training of managers
and scientists in the processes of licensing, intellectual prop-
erty management, and commercialization through intern-
exchange programs and participation in international and
regional seminars and workshops.
Conclusions
Up-scaling its activities in the above-described areas is help-
ing the NIH meet an important part of its global mission to
reduce the burden of diseases that have a devastating effect
particularly on people living in developing countries, and
thus to benefit public health. Moreover, it is expected that
OTT’s activities in international technology transfer will
ensure public availability of new technologies, attract new
R&D resources, obtain returns to public investment, and
stimulate economic development.
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